Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future
Adam J DiPippo1, Neelam K Patel1, Chad M Barnett1
1Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract:
Treatment of metastatic breast cancer (MBC) that is resistant to endocrine therapy presents a significant clinical challenge. The well-known role of cell cycle dysregulation in these patients is partly mediated by cyclin-dependent kinase (CDK) activity. Specific cyclin and CDK complexes regulate cell cycle progression by managing the transition through the cell cycle, and inhibition of CDKs represents an important target for novel agents. First-generation CDK inhibitors (e.g., flavopiridol) were relatively nonselective and had an unacceptable toxicity profile in early trials. Second-generation CDK inhibitors were designed to target the CDK4 and CDK6 (CDK4/6) pathway and have shown promising clinical activity with an acceptable toxicity profile in patients with MBC. Palbociclib is a first-in-class CDK4/6 inhibitor that was granted accelerated U.S. Food and Drug Administration approval in combination with letrozole for the treatment of MBC in the first-line setting (February 2015) as well as in combination with fulvestrant for MBC that had progressed on previous endocrine therapy (February 2016). Other CDK4/6 inhibitors, including ribociclib and abemaciclib, are under investigation as monotherapy and in combination with endocrine or anti-human epidermal growth receptor 2 therapy for the treatment of MBC. Ongoing clinical trials should provide additional information to guide the appropriate use of these agents and identify patient populations that could derive the most benefit.
Insights
Targeting the cell cycle with CDK4/6 inhibitors offers a promising strategy for treating endocrine-resistant metastatic breast cancer (MBC). These targeted therapies demonstrate clinical activity and an improved toxicity profile compared to earlier agents.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Metastatic breast cancer (MBC) resistant to endocrine therapy poses a significant clinical challenge.
- Cell cycle dysregulation, mediated by cyclin-dependent kinases (CDKs), is a key factor in MBC progression.
- First-generation CDK inhibitors exhibited poor selectivity and high toxicity.
Purpose of the Study:
- To review the development and clinical application of CDK4/6 inhibitors in treating metastatic breast cancer.
- To highlight the efficacy and safety of second-generation CDK4/6 inhibitors in endocrine-resistant MBC.
- To discuss the potential of ongoing clinical trials in optimizing the use of these agents.
Main Methods:
- Review of clinical trial data and pharmacological studies on CDK inhibitors.
- Analysis of the mechanism of action of CDK4/6 inhibitors in cell cycle regulation.
- Evaluation of the safety and efficacy profiles of approved and investigational CDK4/6 inhibitors.
Main Results:
- Second-generation CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, show significant clinical activity in MBC.
- Palbociclib is approved in combination with letrozole for first-line treatment and with fulvestrant for pre-treated MBC.
- These inhibitors offer a favorable toxicity profile compared to non-selective CDK inhibitors.
Conclusions:
- CDK4/6 inhibition represents a major advancement in the treatment of endocrine-resistant metastatic breast cancer.
- Further clinical trials are essential to define optimal treatment strategies and identify patient populations most likely to benefit.
- Targeted inhibition of the CDK4/6 pathway provides a valuable therapeutic option for MBC patients.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:39Positive Regulator Molecules
01:45Positive Regulator Molecules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...